Five Prime Therapeutics and Bristol-Myers Squibb sign collaboration agreement to discover novel immuno-oncology therapies for two immune checkpoint pathways
Five Prime Therapeutics, Inc. and Bristol-Myers Squibb Company announced that…
17 March 2014 | By Bristol-Myers Squibb
Five Prime Therapeutics, Inc. and Bristol-Myers Squibb Company announced that they have signed a collaboration agreement for the discovery, development and commercialization of immuno-oncology therapies...